Get the Stockscreener App
9.72
1.02%
-0.10
After Hours:
9.72
Replimune Group Inc stock is traded at $9.72, with a volume of 1.51M.
It is down -1.02% in the last 24 hours and down -2.80% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$9.82
Open:
$9.81
24h Volume:
1.51M
Relative Volume:
0.38
Market Cap:
$762.47M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-3.0759
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
-3.67%
1M Performance:
-2.80%
6M Performance:
+4.63%
1Y Performance:
-19.74%
1-Day Range:
$9.70
$9.99
1-Week Range:
$9.695
$10.05
52-Week Range:
$2.68
$14.80
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
9.72 | 770.31M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - TradingView — Track All Markets
Replimune Group (NASDAQ:REPL) Trading Up 4.8%Should You Buy? - MarketBeat
Replimune Group Inc (HAM:7R8) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Replimune Group Inc. stock overvalued by current metricsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
How Replimune Group Inc. stock trades during market volatility2025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
How institutional buying supports Replimune Group Inc. stockJuly 2025 Snapshot & Daily Growth Stock Investment Tips - ulpravda.ru
Why Replimune Group Inc. stock could benefit from AI revolution2025 Fundamental Recap & Weekly Return Optimization Alerts - Улправда
Is Replimune Group Inc. stock supported by strong fundamentalsJuly 2025 Setups & Smart Swing Trading Alerts - Улправда
Why Replimune Group Inc. stock remains a top recommendationJuly 2025 Pullbacks & Smart Money Movement Alerts - Улправда
Why hedge funds are buying Replimune Group Inc. stock2025 Dividend Review & Free Reliable Trade Execution Plans - DonanımHaber
Aug Catalysts: Why Replimune Group Inc. stock remains a top recommendation - Улправда
What sentiment indicators say about Replimune Group Inc. stockJuly 2025 Outlook & High Return Stock Watch Alerts - Улправда
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - TMX Newsfile
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Replimune Shares Face Mounting Headwinds - AD HOC NEWS
Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential Weakness - simplywall.st
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Replimune Group earns relative strength rating upgrade; hits key benchmark - MSN
What analysts say about Replimune Group Inc stockVolume Spike Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Replimune Group, Inc. $REPL Holdings Trimmed by Braidwell LP - MarketBeat
Replimune Group (NASDAQ:REPL) Director Kapil Dhingra Sells 3,169 Shares - MarketBeat
Replimune Group, Inc. $REPL Shares Sold by Redmile Group LLC - MarketBeat
Replimune Group Director Kapil Dhingra Sells All Shares - TradingView — Track All Markets
[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan
Replimune Group, Inc. $REPL Shares Sold by Marshall Wace LLP - MarketBeat
Nan Fung Group Holdings Ltd Lowers Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq
Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat
Replimune Stock Presents a Complex Investment Narrative - AD HOC NEWS
Saturn V Capital Management LP Takes $1.20 Million Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group CEO Sushil Patel Sells 10,000 Shares - TradingView
CEO Patel Sells 10,000 ($111.3K) Of Replimune Group Inc [REPL] - TradingView
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review
Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by Replimune Group, Inc. - The National Law Review
Will Replimune Group Inc. stock reach all time highs in 2025Oil Prices & Risk Managed Investment Strategies - BỘ NỘI VỤ
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman (PR Newswire) - Aktiellt
What Is Driving Replimune Stock’s 98% Surge Today? - MSN
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can One97 Communications Limited Deliver Consistent Free Cash FlowsVolume Spike Alerts & Swing Trade Smarter With Data Insights - earlytimes.in
Replimune Group Inc. stock volume spike explainedWeekly Stock Analysis & Short-Term Trading Alerts - newser.com
How Replimune Group Inc. stock reacts to global recession fearsMarket Trend Review & Smart Investment Allocation Insights - newser.com
Replimune Group (NASDAQ:REPL) Insider Sells $47,392.80 in Stock - MarketBeat
Will Replimune Group Inc. stock deliver shareholder valueQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - newser.com
Using AI based signals to follow Replimune Group Inc.Bond Market & Long Hold Capital Preservation Tips - newser.com
Trend analysis for Replimune Group Inc. this weekWeekly Market Outlook & Low Volatility Stock Suggestions - newser.com
Replimune Group Executives Sell Shares for Tax Obligations - TradingView
Why Replimune Group Inc. stock is a must watch in 2025July 2025 Levels & Weekly High Momentum Picks - newser.com
Smart tools for monitoring Replimune Group Inc.’s price actionWeekly Trade Summary & Accurate Entry and Exit Point Alerts - newser.com
Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):